Recent Publications by V.I. Technologies Incorporated: |
Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents.
BACKGROUND: Cytomegalovirus (CMV) is transmitted by transfusion of... | 18th October, 2006
| V.I. Technologies, Inc., Watertown, Massachusetts, USA.
| Transfusion. 2006 Sep;46(9):1580-8.
DOI Direct Link |
Inactivation of Gram-negative and Gram-positive bacteria in red cell concentrates using INACTINE PEN110 chemistry.
BACKGROUND AND OBJECTIVES: The risk of transfusion-transmitted bacterial... | 30th March, 2005
| V. I. Technologies, Inc., Watertown, MA 02472, USA.
| Vox Sang. 2004 Oct;87(3):143-9.
DOI Direct Link |
Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.
BACKGROUND AND OBJECTIVES: Two different leucocyte-inactivation... | 14th October, 2004
| V. I. Technologies, Inc., Watertown, MA 02465, USA.
| Vox Sang. 2004 Jul;87(1):1-9.
DOI Direct Link |
Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry.
BACKGROUND: The transmission of parasites, including Babesia, plasmodia,... | 3rd June, 2004
| V.I. Technologies, Inc., Watertown, Massachusetts 02472, USA.
| Transfusion. 2004 May;44(5):731-8.
DOI Direct Link |
Inactivation of mycoplasma species in blood by INACTINE PEN110 process.
BACKGROUND: Mycoplasmas have been associated with multiple acute and... | 24th March, 2004
| V. I. Technologies, Inc., Watertown, Massachusetts 02472, USA.
| Transfusion. 2004 Feb;44(2):286-93.
|
Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies.
BACKGROUND: The novel PEN110 chemistry (INACTINE, V.I. Technologies)... | 24th October, 2003
| V.I. Technologies (VITEX), Watertown, Massachusetts 02472, USA.
| Transfusion. 2003 Oct;43(10):1386-93.
|
West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation.
BACKGROUND: The outbreak of West Nile virus (WNV) is the most recent... | 25th September, 2003
| V.I. Technologies, Inc., Watertown, Massachusetts 02472, USA.
| Transfusion. 2003 Aug;43(8):1029-37.
|
Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry.
BACKGROUND AND OBJECTIVES: The risk of transmission of blood-borne... | 12th July, 2003
| V. I. Technologies, Inc., 134 Coolidge Avenue, Watertown, MA 02472, USA.
| Vox Sang. 2002 Nov;83(4):313-23.
|
Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.
BACKGROUND: Yersinia enterocolitica, Pseudomonas fluorescens, and P.... | 25th April, 2003
| V. I. Technologies, Inc., Watertown, Massachusetts, USA.
| Transfusion. 2003 Feb;43(2):135-42.
|
Inactivation of HIV in blood.
BACKGROUND: The residual risk of HIV infection after HIV screening tests... | 5th December, 2002
| V.I. Technologies, Inc., 134 Coolidge Avenue, Watertown, MA 02472, USA.
| Transfusion. 2002 Oct;42(10):1308-17.
|
Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
Various approaches are being developed for virus inactivation of red blood... | 15th July, 2000
| V.I. Technologies, Inc. (Vitex), New York, NY 10032, USA.
| Dev Biol (Basel). 2000;102:149-55.
|
